Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 727-730

  Yamamoto, Michiko ^a   Kurita, Akinobu ^b   Asahara, Takashi ^b   Takakura, Akira ^a   Katono, Ken ^a   Iwasaki, Maiko ^a   Ryuge, Shinichiro ^a   Wada, Mayuko ^a   Onoda, Sayaka ^a   Yanaihara, Tomoko ^a   Yokoba, Masanori ^a   Mitsufuji, Hisashi ^a   Nishii, Yasuto ^a   Fukui, Tomoya ^a   Masuda, Noriyuki ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Adsorption; Diarrhea; Intestinal microorganisms; Irinotecan; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BETA GLUCURONIDASE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; LACTONE;

ADSORPTION; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL WALL; BACTERIUM CULTURE; BILE; CONTROLLED STUDY; CULTURE MEDIUM; DIARRHEA; DRUG CONJUGATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; HYDROPHOBICITY; INTESTINE FLORA; INTESTINE FLUID; LIPOPHILICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUPERNATANT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIA; CAMPTOTHECIN; DIARRHEA; INTESTINES; MALE; RATS; RATS, WISTAR;

EID: 54949089595     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000066     Document Type: Article

References (20)

1. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
2. Masuda N, Kudoh S and Fukuoka M: Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol 24: 3-26, 1996.
3. Hecht JR: Gastrointestinal toxicity of irinotecan. Oncology 12: 72-78, 1998.
4. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
5. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998.
6. Rivory LP and Robert J: Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176-179, 1995.
7. Itoh T, Takemoto I, Itagaki S, Sasaki K, Hirano T and Iseki K: Biliary excretion of irinotecan and its metabolites. J Pharm Pharm Sci 7: 13-18, 2004.
8. Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y and Bouscarel B: Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62: 179-187, 2002.
9. Ikuno N, Soda H, Watanabe M and Oka M: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87: 1876-1883, 1995.
10. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T: Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752-3757, 1996.
11. Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A and Di Palma M: New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 30: 555-562, 2004.
12. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D and Cvitkovic E: Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16: 2745-2751, 1998.
13. Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L and Moore MJ: Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 22: 4410-4417, 2004.
14. Holdeman LV, Cato EP and Moore WEC: Anaerobe Laboratory Manual. 4th edition, Virginia Polytechnic Institute and State University, Blacksburg, 1977.
15. Kurita A and Kaneda N: High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J Chromatogr B Biomed Sci Appl 724: 335-344, 1999.
16. Kaneda N, Hosokawa Y and Yokokura T: Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography. Biol Pharm Bull 20: 815-819, 1997.
17. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361: 2235-2242, 2003.
18. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T: Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42: 280-286, 1998.
19. Meincke BE, Kranz RG and Lynch DL: Effect of irgasan on bacterial growth and its adsorption into the cell wall. Microbios 28: 133-147, 1980.
20. Khanna R, Morton CL, Danks MK and Potter PM: Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60: 4725-4728, 2000.